北京神州细胞生物技术集团股份公司 2025年年度业绩预告

Group 1 - The company forecasts a net loss attributable to shareholders of the parent company for the year 2025, estimated between -580 million and -520 million yuan [3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -563 million and -503 million yuan [4] - Research and development investment for 2025 is projected to be between 830 million and 870 million yuan [5] Group 2 - The previous year's total profit was 112.35 million yuan, with a net profit attributable to shareholders of 111.95 million yuan [7] - The net profit after deducting non-recurring gains and losses for the previous year was 474.41 million yuan [7] - Research and development investment in the previous year was 936.02 million yuan [8] Group 3 - The decline in sales revenue is attributed to the deepening of industry medical insurance cost control policies and significant price reductions of the core product, leading to a substantial decrease in overall operating income compared to the previous year [8] - Increased commercialization investments for newly approved products, including academic promotion and sales team formation, have led to a noticeable rise in sales expenses in the short term [8] - The company continues to maintain a high level of R&D investment as multiple ongoing projects have entered critical confirmatory clinical trial stages, impacting current profitability [8]